 Twist Bioscience Corp NASDAQ: TWST and Victorian Clinical Genetic Services VCGS have developed a novel whole-exome capture assay, which utilizes Next Generation Sequencing to conduct analysis and sequencing of the entire exome. In particular, the assay can target difficult to cover, non-coding regions outside the normal exome known to contain pathogenic variants. 